Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;22(3):349-366.
doi: 10.1007/s40257-021-00586-8. Epub 2021 Feb 15.

Eczematous Drug Eruptions

Affiliations
Review

Eczematous Drug Eruptions

Amy E Blum et al. Am J Clin Dermatol. 2021 May.

Abstract

Eczematous drug eruptions are a heterogenous group of skin reactions that resemble eczema both clinically and histologically. We reviewed the literature and cataloged the systemically administered medications that cause these eruptions, along with their characteristic clinical presentations. We identified three primary pathophysiologic etiologies: (1) cutaneous immunomodulation, (2) skin dehydration, and (3) delayed hypersensitivity. Notably, eczematous eruptions caused by altered immunity in the skin may be increasing in incidence as some responsible drugs, in particular biologic therapies (such as tumor necrosis factor-α and interleukin-17 inhibitors) and targeted cancer treatments (including immune checkpoint inhibitors and epidermal growth factor receptor inhibitors), become more commonly employed in clinical practice. Other notable causes of eczematous eruptions include antiviral agents for hepatitis C virus and cardiovascular medications in elderly individuals, and notable subtypes of eczematous reactions include systemic contact dermatitis and photoallergic reactions, which are also discussed. The diagnostic gold standard is drug rechallenge and most reactions may be treated effectively with emollients, topical corticosteroids, and oral antihistamines.

PubMed Disclaimer

References

    1. Apaydin R, Dökmeci Ş, Bayramgürler D, Yildirim G. Drug eruptions: a study including all inpatients and outpatients at a dermatology clinic of a university hospital. J Eur Acad Dermatol Venereol. 2000;14:518–20. - PubMed
    1. Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998;139:49–58. - PubMed
    1. Borch JE, Andersen KE, Bindslev-Jensen C. The prevalence of acute cutaneous drug reactions in a Scandinavian university hospital. Acta Derm Venereol. 2006;86:518–22. - PubMed
    1. Segaert S, Hermans C. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am J Clin Dermatol. 2017;18:771–87. - PubMed
    1. Cossio M-L, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study. J Cutan Med Surg. 2020;24(4):333–9. - PubMed

MeSH terms

LinkOut - more resources